Your session is about to expire
← Back to Search
Mirvetuximab Soravtansine for Ovarian Cancer (MIRASOL Trial)
MIRASOL Trial Summary
This trial is testing a new drug, mirvetuximab soravtansine, to see if it is more effective and has fewer side effects than existing chemotherapy drugs for people with ovarian cancer.
MIRASOL Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMIRASOL Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 96 Patients • NCT03106077MIRASOL Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have previously been treated with MIRV or drugs targeting FRα.I have a serious heart condition.I do not have severe numbness or pain in my hands or feet.I have brain metastases that are either untreated or causing symptoms.I have a history of multiple sclerosis, demyelinating disease, or Lambert-Eaton syndrome.I have recovered from side effects of previous cancer treatments.I do not have any serious illnesses or active infections.I have had radiotherapy that affected a significant part of my bone marrow.I have had a stroke in the last 6 months.I am not pregnant or breastfeeding.I have had cancer other than my current one in the last 3 years.I've had 1-3 cancer treatments and need a single-agent therapy next.My tumor is positive for FRα based on a specific test.I have a history of liver cirrhosis.I have ongoing eye problems or have had a cornea transplant.My condition did not improve with platinum-based chemotherapy.I had major surgery over 4 weeks ago and have recovered from it.You had a bad reaction to other medications like the study drug.You must have at least one specific spot of disease that can be measured according to certain guidelines.I am fully active or restricted in physically strenuous activity but can do light work.I have been diagnosed with a serious type of ovarian, peritoneal, or fallopian tube cancer.My ovarian cancer is of a specific type (endometrioid, clear cell, mucinous, sarcomatous, mixed, or low-grade).I am not under any form of detention, involuntary psychiatric care, legal protection, or guardianship that prevents me from consenting.Your condition got worse in imaging tests after your last treatment.Women of childbearing potential must have a negative pregnancy test within 4 days before taking the study drug.My cancer did not respond to initial platinum-based chemotherapy.I am willing to provide a sample of my tumor for testing.I am a woman aged 18 or older.I agree to use effective birth control during and after the study.I have been diagnosed with a type of lung disease that is not caused by an infection.My blood, liver, and kidney functions are all within normal ranges.You are required to take supplements that contain folate.
- Group 1: Investigator's choice of chemotherapy
- Group 2: mirvetuximab soravtansine (MIRV; IMGN853)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical condition is Mirvetuximab Soravtansine usually prescribed for?
"Mirvetuximab Soravtansine is a medication used to treat advanced soft tissue sarcoma and advanced cervical cancer. It can also help patients with neoplasms and esophageal neoplasms malignant."
What are known side effects of Mirvetuximab Soravtansine?
"The Power team has given Mirvetuximab Soravtansine a safety rating of 3. This is because Phase 3 clinical trials have shown some efficacy and multiple rounds of data have supported its safety."
Are there any other ongoing or completed investigations utilizing Mirvetuximab Soravtansine?
"The first mirvetuximab soravtansine clinical trial was conducted in 1997 at Spectrum Health Hospital - Butterworth Campus. Since then, there have been a total of 1822 completed trials. Out of these, 1229 are active and ongoing, with a considerable amount taking place in Savannah, Georgia."
Have similar tests been conducted before?
"Mirvetuximab Soravtansine has undergone 1229 clinical trials in 3350 cities and 81 countries. The first study occurred in 1997 and, sponsored by Alfacell, it involved 300 patients. Phase 3 of the trial concluded with drug approval. Since then, 1822 studies have completed."
Could you please give the total number of people enrolling in this medical study?
"Presently, this clinical trial is not enrolling patients. According to the study's last update on October 28th, 2022, it is unclear when recruitment will open again. There are 594 other studies seeking patients with fallopian tubes cancer and 1229 studies searching for patients that match the criteria for Mirvetuximab Soravtansine."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Average response time
- < 2 Days
Typically responds via
Most responsive sites:
- Tom Baker Cancer Centre: < 48 hours
Share this study with friends
Copy Link
Messenger